August 10, 2017 | SOURCE: PR NEWSWIRE

Regen BioPharma, Inc. Addresses Potential Impact of Recent Bristol Myers Squibb’s $2.3 Billion Acquisition of IFM Therapeutics. Small molecule biotech companies fetching trophy values from large Pharma